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Wednesday, February 19, 2014 771athe cTnTT204E-mediated effects on cardiac contractile function. Our novel
observations have clinical relevance because increased activity of various
PKC isoforms and upregulation of b-MHC are observed in failing human
hearts.
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Mutations in the nebulin gene (NEB), skeletal muscle alpha-actin1 gene
(ACTA1), beta-tropomyosin 2 gene (TPM2) and alpha-tropomyosin 3 gene
(TPM3) lead to thin filament myopathies, such as nemaline myopathy (NM),
congenital fiber type disproportion (CFTD) and cap disease (CAP). A hallmark
feature of these myopathies is muscle weakness. Here, we aimed to elucidate
the effect of NEB, ACTA1, TPM2 and TPM3 mutations on thin filament length
by determining the sarcomere length-dependence of force.
Quadriceps biopsies from NM, CFTD, and CAP patients (n=18) with mutations
in the NEB, ACTA1, TPM2 or TPM3 were compared to biopsies from controls
(n=3). Using permeabilized muscle fibers, maximal active tension was deter-
mined at incremental sarcomere lengths (range 2.0-3.5 mm) to obtain the
force-sarcomere length relationship.
The maximal active tension (Fmax (in mN/mm2, mean5SD)) was signifi-
cantly lower in biopsies from severe NEB (1855), mild NEB (7655), severe
ACTA1 (54513) and severe TPM3 (95514) patients compared to biopsies of
controls (164517), whereas no significant changes in Fmax were observed in
biopsies from mild ACTA1 (139527), mild TPM2 (120158) and mild TPM3
(156513) patients. The classification of severity is based on the age of onset.
No shift in the force-sarcomere length relationship was observed in mild
ACTA1, TPM3 and TPM2 patients. Interestingly, in contrast to patients with
ACTA1, TPM2 and TPM3 mutations, fiber preparations from both mildly
and severly affected NEB patients showed a leftward shift of the force-
sarcomere length relationship (a leftward shift of the force-sarcomere length
relationship indicates shorter thin filaments).
Our data suggest that mutations in NEB result in the most pronounced changes
in thin filament length. Insights in the mechanisms underlying weakness in pa-
tients with thin filament mutations are necessary to improve specific treatment
strategies.
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The mechanisms underlying most forms of Distal Arthrogryposis (DA), a group
of congenital contracture syndromes, are unknown. Our previous functional
studies from adult individuals with DA caused by the heterozygous embryonic
myosin heavy chain mutation,MYH3 R672C, showed that the time required by
DA skinned skeletal myofibers to relax completely after calcium-induced
contraction was several-fold longer than controls (Racca et al. (2010) Biophys
J 98:542-3a). Here we measured force and kinetics of activation & relaxation,
and compared chemomechanical analysis using myofibrils and myofibers
sampled from gastrocnemius muscle from two affected individuals vs. three
control (non-DA) individuals. The prolonged relaxation was reflected in iso-
lated myofibrils from DA patients, as 50% relaxation time from maximal acti-
vation was 36% longer, and 90% relaxation time was prolonged by 58%. The
kinetics of the slow phase of relaxation were significantly slower, in both the
rate and duration (DA: kREL,SLOW=0.3650.07s
1;tREL,SLOW=285521ms vs.
Control: 0.7950.18s1;199523ms), implying slower cross-bridge release.
Use of ADP prolonged relaxation of control samples to a greater extent than
DA preparations, suggesting that slower ADP release from myosin in DA
myofibrils may be the mechanism of slower relaxation and cross-bridge release.
We also found that both mRNA and protein for this "embryonic" myosin (gene
MYH3) were present in adult skeletal muscle, such that a small amount of
this slower myosin may prolong relaxation. Although the mechanism that
leads to the congenital contractures must begin prenatally, these results suggest
that MYH3 R672H also affects ongoing function of adult skeletal muscle. Un-
derstanding the mechanism by which myosin mutations affect muscle cell
contractility could provide a model for exploring the pathogenesis of more
common contractures such as idiopathic clubfoot and facilitate the develop-
ment of novel therapeutic approaches. Supported by F31AR06300(A.R.),
5K23HD057331(A.B.), HD048895(M.B.,M.R.).3892-Pos Board B620
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In Familial Hypertrophic Cardiomyopathy (FHC) 1/3 of the patients are
affected by mutations in the ß-myosin heavy chain (ß-MyHC), the myosin iso-
form of the ventricle and of slow skeletal muscle fibers in humans. Yet, not
much is known about (i) direct effects of specific ß-MyHC-mutations on
acto-myosin function, and (ii) how these mutations may trigger development
of the FHC-phenotype.
To address these questions, we analyzed the effects of the ß-MyHC-mutation
R453C on contractile properties of slow (type I) fibers from the M. soleus of
a severely affected FHC patient. We found an about 12% higher isometric
force, 15% faster rate constant of force redevelopment (ktr), 10% higher
isometric ATPase activity and essentially unchanged tension cost. Together
with only slightly higher fiber stiffness in rigor, a main part of the increase
in isometric force appears to be due to altered cross-bridge cycling kinetics,
specifically an increase in fapp, the rate constant for the cross-bridge
transition into force generating states. Currently we investigate whether
increased force generated per myosin head e.g., by a larger y0-value also
contributes.
Relative quantification of mutated vs. wildtype ß-MyHC-mRNA of the hetero-
zygous patient revealed a fraction of about 35% for the R453C-mRNA.
Assuming similar abundance of mutated MyHC at the protein level, as we
had found in other FHC-mutations, about a third of the ß-myosin heads in
the sarcomeres carry the mutation. Thus, force contribution of the mutated
myosin head population is about 40% increased. A larger variability in pCa50
among individual fibers with mutation R453C vs. control fibers, as we had
seen for other FHC-mutations, suggests unequal expression of mutated myosin.
We hypothesize that unequal expression of mutated myosin in individual car-
diomyocytes causes imbalanced force generation and initiates functional
impairment of the myocardium in FHC.
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Familial hypertrophic cardiomyopathy (FHC) is a disease of the heart caused
by autosomal dominant mutations in genes coding for all major sarcomeric pro-
teins, including the myosin regulatory light chain (RLC). In this report, we have
explored the rescue strategies to ameliorate the malignant cardiomyopathy
phenotype induced by an aspartic acid to valine substitution (D166V) in the
RLC. Previous studies on porcine reconstituted preparations showed that the
phosphorylation mimic (S15D) in the background of the D166V mutation
(S15D-D166V) restored the calcium sensitivity of force and improved Vmax
of myosin ATPase that were largely compromised by the D166V mutation.
Transgenic "Rescue Mice" carrying the S15D-D166V mutation have been
generated and subjected to structural and functional measurements. Small angle
X-ray studies on freshly skinned papillary muscle fibers revealed that a D166V-
induced reorganization in cross-bridge mass distribution was partially reversed
in Rescue Mice (abnormally increased I1,1/I1,0 ratio observed in Tg-D166V fi-
bers returned to the value near Tg-WT). Noteworthy, pseudo-phosphorylation
of D166V significantly restored fiber elasticity allowing for changes in the
cross-bride mass distribution on stretch. In vivo cardiac morphology and func-
tion were assessed by non-invasive echocardiography followed by invasive left
ventricular pressure-volume measurements (P-V loops). Echocardiography
assessment confirmed hypertrophy in Tg-D166V mice showing an increased
posterior wall thickness in systole. Invasive hemodynamics showed diastolic
and systolic dysfunction in Tg-D166V mice. The end-systolic P-V relationship,
a measure of heart contractility, which was largely reduced in Tg-D166V mice
was completely ameliorated in Rescue Mice. In addition, the maximum dP/dt -
End-Diastolic Volume relation, which was compromised in Tg-D166V was
fully reversed in Rescue Mice. In conclusion, our results suggest that
pseudo-phosphorylation of myosin RLC can mitigate both the structural and
functional abnormalities of the FHC heart. Supported by NIH-HL108343 and
HL071778 (DSC).
